S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Authors: N. Daver, M. Alfayez, G. Garcia-Manero, H. Abbas, S. Basu, M. Konopleva, E. Jabbour, J. E. Cortes, F. Ravandi, T. M. Kadia, C. DiNardo, R. Assi, P. Sherry, M. Andreeff, Z.E. Estrov, N. Pemmaraju, K. Takahashi, J. Ning, G. Nogueras Gonzalez, S.M. Kornblau, J. Matthews, W.R. Flores, J.P. Allison, P. Sharma, H. Kantarjian

Published: 2019-06-17

DOI: 10.1097/01.hs9.0000564708.44567.4d

Source: Full article

---

Abstract

No abstract found.